The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Jan. 04, 2018
Applicant:

Helix Biopharma Corp., Richmond Hill, CA;

Inventors:

Heman Lap Man Chao, Aurora, CA;

Wah Yau Wong, Edmonton, CA;

Baomin Tian, Edmonton, CA;

Marni Diane Uger, Richmond Hill, CA;

Assignee:

Helix BioPharma Corp., Ontario, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61K 35/17 (2015.01); A61K 47/68 (2017.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 35/17 (2013.01); A61K 39/001109 (2018.08); A61K 47/6815 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/22 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/35 (2013.01); C12N 2501/165 (2013.01); C12N 2510/00 (2013.01);
Abstract

Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VEGFR. More specifically, the cells are CAR-T cells recognizing VEGFR-2 on solid tumors, uses thereof, compositions thereof and methods of making. The invention includes therapeutic methods to treat VEGFR-2 dependent cancers targeting tumor angiogenesis. A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof.


Find Patent Forward Citations

Loading…